Month: April 2021

NEW HAVEN, Conn., April 26, 2021 (GLOBE NEWSWIRE) — Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that currently, the contracted annualized revenues from signed customers for its HemeScreen POL (Physician Office Laboratory) testing system exceed $750,000 and for the reasons set forth below, by Q4-2021 this cohort is expected to result in reported quarterly revenues with an annualized run rate of $1,000,000. With an additional pipeline of over 30 prospective customers nationwide, Precipio currently reaffirms its forecast that product revenues will reach approximately 50% of pathology revenue by the fourth quarter of 2021. The annualized reported revenues from the cohort of current signed customers are expected to increase to $1,000,000 by Q4-2021 because newly signed customers typically make smaller contractual...

MALVERN, Pa., April 26, 2021 (GLOBE NEWSWIRE) — Vishay Intertechnology, Inc. (NYSE: VSH) today introduced a new extended temperature “E” option for its TSSP77038 infrared (IR) sensor module in the Heimdall package. Designed to meet the special requirements of outdoor applications, the Vishay Semiconductors TSSP77038ETR has been enhanced with a storage temperature range of -40 °C to +110 °C and an operating temperature range of -30 °C to +85 °C. Standard packages for IR sensor modules offer limited storage and operating temperature ranges of -25 °C to +85 °C. With the robust design of its Heimdall package, the TSSP77038ETR is able to handle a wider temperature range, making the device ideal for operation in applications exposed to direct sunlight and large temperature variations, including garage door light barrier systems, door...

Stock Exchange Release April 26th, 2021 at 06.00 pm Due to delays affecting the application process, the management of BBS-Bioactive Bone Substitutes Plc (“BBS”, “Company”) has changed its estimate regarding the submission date of the ARTEBONE® products CE marking application. The company expects to submit the application during August this year. Earlier, the company had estimated that the application could be submitted during April this year. The delay is due to equipment, material and service deliveries to Oulu laboratory and Reisjärvi factory being delayed significantly due to the COVID-19 situation. Repairing a detected structural fault in Reisjärvi factory’s clean room has delayed the start of the validation process. In addition, the results from the animal testing have been delayed significantly. We expect to receive the final report...

Yhtiötiedote 26.4.2021, klo 18:00 BBS-Bioactive Bone Substitutes Oyj:n (“BBS”, “Yhtiö”) johto on muuttanut arviotaan Yhtiön ARTEBONE®-tuotteen CE-merkintälupahakemuksen jättämisestä hakuprosessiin liittyvien viiveiden seurauksena. Yhtiö arvioi nyt jättävänsä CE-merkintähakemuksen tämän vuoden elokuussa. Aikaisemmin arvioitiin, että hakemus saadaan jätettyä tämän vuoden huhtikuun aikana. Aikataulumuutoksen syynä on, että laite-, materiaali- ja palvelutoimitukset Reisjärven tehtaalle ja Oulun laboratorioon ovat merkittävästi viivästyneet koronan vuoksi. Reisjärven tehtaalla olevissa puhdastiloissa on ilmennyt ilmastoinnin rakennevirhe, jonka korjaaminen on viivästyttänyt ARTEBONE®-tuotteen validointiprosessien aloitusta. Lisäksi eläinkoetulosten valmistuminen on viivästynyt merkittävästi aiemmin tiedotetusta. Lopullista raporttia odotetaan...

ROSEVILLE, Calif., April 26, 2021 (GLOBE NEWSWIRE) — via InvestorWire — InnerScope Hearing Technologies Inc. (OTC: INND) (“InnerScope”), an emerging and disruptive leader in the Direct-to-Consumer Hearing Device and Hearing Health Technology space, announces that it has signed a Letter of Intent Agreement (the “LOI Agreement”) with Audio Cardio Inc. dba AudioCardio™(“AudioCardio“), granting InnerScope a worldwide license (excluding Japan, Korea, and China) for full commercial rights to develop, market, and sell an InnerScope branded subscription-based mobile app (InnerScope’s “Hearing Therapy App”) utilizing AudioCardio™ proprietary software which has clinically proven Threshold Sound Conditioning technology, i.e., “Physical Therapy for Your Hearing.” Additional...

SSH Communications Security Corporation announced on January 29, 2021, that its subsidiary Kyberleijona Oy has agreed to acquire all shares of Deltagon Oy. Kyberleijona Oy has received all required regulatory approvals, and other closing conditions of the transaction have been fulfilled. As a result of this, the acquisition of Deltagon Oy is completed. The details of the transaction are described in the stock exchange release published on January 29, 2021. SSH’s CEO, Dr. Teemu Tunkelo, comments: ”We have now closed the acquisition of Deltagon. This acquisition is a major step in our transition to a subscription-based business model and in offering complete solutions with critical cybersecurity products. The acquisition also broadens our offerings portfolio and customer base. I wish the entire Deltagon staff warmly welcome as a part...

SSH Communications Security Oyj tiedotti 29.1.2021 yrityskaupasta, jossa SSH Communications Security Oyj:n tytäryhtiö Kyberleijona Oy ostaa Deltagon Oy:n koko osakekannan. Kyberleijona Oy on saanut tarvittavat viranomaishyväksynnät, ja kaupan muut täytäntöönpanoehdot ovat täyttyneet. Näin ollen Deltagon Oy:n yrityskauppa on saatu päätökseen. Yrityskaupan tarkemmat tiedot on kuvattu 29.1.2021 julkaistussa pörssitiedotteessa. SSH:n toimitusjohtaja Teemu Tunkelo kommentoi: ”Deltagon-yritysostomme on nyt viety päätökseen. Tämä yritysosto on merkittävä askel tilauspohjaiseen liiketoimintamalliin siirtymisessä sekä kriittisten kyberturvallisuustuotteiden kokonaisratkaisuiden tarjoamisessa. Kauppa laajentaa ohjelmistoportfoliotamme ja asiakaspohjaamme. Toivotan Deltagon Oy:n osaavan henkilökunnan lämpimästi tervetulleeksi osaksi kyberturvaohjelmistojen...

PRINCETON, N.J., April 26, 2021 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company has achieved the second milestone under its licensing agreement for ADXS31-164, also known as ADXS-HER2, to OS Therapies for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, OS Therapies, in collaboration with the Children’s Oncology Group (COG), is responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. OS Therapies recently completed a financing, triggering the second milestone payment. Under the agreement, Advaxis has the opportunity to receive additional clinical, regulatory, and sales-based...

MONTREAL, April 26, 2021 (GLOBE NEWSWIRE) — TC Transcontinental (TSX: TCL.A TCL.B) is proud to respond to the Québec government’s call for businesses to support the health and social services network in its COVID-19 vaccination campaign. According to the order of priority established by public health, the company will offer the supervised vaccination to the local population, TC Transcontinental employees and their families starting at the end of May. The company’s vaccination centre will be in Montréal’s Rivière-des-Prairies–Pointe-aux-Trembles borough, given TC Transcontinental’s significant presence in the East end of Montreal. It will be located at the head office of the company’s Distribution activities at 8000 Blaise-Pascal Avenue, Rivière-des-Prairies, close to the Transcontinental Transmag (printing – Anjou),...

MONTRÉAL, 26 avr. 2021 (GLOBE NEWSWIRE) — TC Transcontinental (TSX : TCL.A TCL.B) répond avec fierté à l’appel du gouvernement du Québec lancé aux entreprises afin de soutenir le réseau de la santé et des services sociaux dans sa campagne de vaccination contre la COVID-19. Selon l’ordre de priorité établi par la santé publique, l’entreprise offrira la vaccination supervisée à la population locale, aux employés de TC Transcontinental et à leurs familles dès la fin du mois de mai. Le pôle de vaccination de l’entreprise sera établi dans l’arrondissement Rivière-des-Prairies–Pointe-aux-Trembles de la Ville de Montréal, en raison de la présence importante de TC Transcontinental dans l’Est de Montréal. Il sera localisé au siège des activités de Distribution de la Société, au 8000, avenue Blaise-Pascal à Rivière-des-Prairies, à proximité...